The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
subcutaneous injection
subcutaneous injection
Cmax following single-dose administration
Time frame: 0 through 72 hours post-dose
AUC following single-dose administration
Time frame: 0 through 72 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.